Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

340.50DKK
14 Jun 2019
Change (% chg)

-- (--)
Prev Close
kr.340.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,464,387
52-wk High
kr.349.70
52-wk Low
kr.265.15

Select another date:

Wed, Jun 12 2019

BRIEF-Novo Nordisk: PIONEER 6 Trial Achieved Its Primary Endpoint

* SAID ON TUESDAY THE PIONEER 6 TRIAL ACHIEVED ITS PRIMARY ENDPOINT BY DEMONSTRATING NON-INFERIORITY OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) WITH ORAL SEMAGLUTIDE COMPARED WITH PLACEBO, BOTH IN ADDITION TO STANDARD OF CARE

Oral Novo Nordisk diabetes drug poses no more heart risk than placebo: study

An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

CORRECTED-Oral Novo Nordisk diabetes drug poses no more heart risk than placebo -study

June 11 An experimental oral form of a Novo Nordisk drug for type 2 diabetes posed no greater risk of serious heart problems or death than a placebo in patients at high risk for such complications, according to data from a large study presented on Tuesday.

Novo Nordisk profit tops forecast as new diabetes drug shines

COPENHAGEN Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.

UPDATE 2-Novo Nordisk profit tops forecast as new diabetes drug shines

COPENHAGEN, May 3 Danish drugmaker Novo Nordisk beat first-quarter operating profit forecasts on Friday, helped by higher sales of its biggest new drug hope, a treatment for type 2 diabetes.

Drugmaker Novo Nordisk first-quarter profit beats expectations

COPENHAGEN, May 3 Danish drugmaker Novo Nordisk posted first-quarter operating profit above forecasts on Friday as it sold more of its newest innovative drug to combat diabetes and nudged up its 2019 outlook reported in Danish crowns.

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Novo Nordisk and Gilead team up to test fatty liver disease treatment

COPENHAGEN, April 12 Novo Nordisk and Gilead Sciences will join forces on a clinical trial combining drugs from the two pharmaceutical firms to treat a progressive fatty liver disease known as NASH.

Only first whistleblower entitled to collect in Novo Nordisk settlement – judge

A former Novo Nordisk employee deserves 15 percent of a $46.5 million settlement between the drugmaker and the U.S. Justice Department resolving claims its marketing downplayed its diabetes medication Victoza's cancer risks, a federal judge has ruled.

Novo Nordisk submits diabetes pill for U.S. approval

COPENHAGEN Novo Nordisk has submitted its oral semaglutide drug, a pill it hopes will transform the diabetes market, for approval in the United States.

Select another date: